Introduction: Patients with acute kidney injury (AKI) or end stage kidney disease (ESKD) may require continuous renal replacement therapy (CRRT) as a supportive intervention. While CRRT is effective at achieving solute control and fluid balance, the indiscriminate nature of this procedure raises the possibility that beneficial substances may similarly be removed. Hepcidin, an antimicrobial peptide with pivotal roles in iron homeostasis and pathogen clearance, has biochemical properties amenable to direct removal via CRRT. We hypothesized that serum hepcidin levels would significantly decrease after initiation of CRRT. Methods: In this prospective, observational trial, we enrolled 13 patients who required CRRT: 11 due to stage 3 AKI, and 2 due to critical illness in the setting of ESKD. Plasma was collected at the time of enrollment, and then plasma and effluent were collected at 10:00 a.m. on the following 3 days. Plasma samples were also collected from healthy controls, and we compared hepcidin concentrations in those with renal disease compared to normal controls, evaluated trends in hepcidin levels over time, and calculated the hepcidin sieving coefficient. Results: Plasma hepcidin levels were significantly higher in patients initiating CRRT than in normal controls (158 ± 60 vs. 17 ± 3 ng/mL respectively, p < 0.001). Hepcidin levels were highest prior to CRRT initiation (158 ± 60 ng/mL), and were significantly lower on day 1 (102 ± 24 ng/mL, p < 0.001) and day 2 (56 ± 14 ng/mL, p < 0.001) before leveling out on day 3 (51 ± 11 ng/mL). The median sieving coefficient was consistent at 0.82–0.83 for each of 3 days. Conclusions: CRRT initiation is associated with significant decreases in plasma hepcidin levels over the first 2 days of treatment regardless of indication for CRRT, or presence of underlying ESKD. Since reduced hepcidin levels are associated with increased mortality and our data implicate CRRT in hepcidin removal, larger clinical studies evaluating relevant clinical outcomes based on hepcidin trends in this population should be pursued.

1.
Hoste
EA
,
Bagshaw
SM
,
Bellomo
R
,
Cely
CM
,
Colman
R
,
Cruz
DN
.
Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study
.
Intensive Care Med
.
2015
;
41
(
8
):
1411
23
.
2.
Maynar Moliner
J
,
Honore
PM
,
Sánchez-Izquierdo Riera
JA
,
Herrera Gutiérrez
M
,
Spapen
HD
.
Handling continuous renal replacement therapy-related adverse effects in intensive care unit patients: the dialytrauma concept
.
Blood Purif
.
2012
;
34
(
2
):
177
85
.
3.
Cho
KC
,
Himmelfarb
J
,
Paganini
E
,
Ikizler
TA
,
Soroko
SH
,
Mehta
RL
.
Survival by dialysis modality in critically ill patients with acute kidney injury
.
J Am Soc Nephrol
.
2006
;
17
(
11
):
3132
8
.
4.
Honore
PM
,
Barreto Gutierrez
L
,
Kugener
L
,
Redant
S
,
Attou
R
,
Gallerani
A
.
Hepcidin is described as the master regulator of iron: could its removal by CRRT lead to iron dysmetabolism in the critically ill
.
Crit Care
.
2020
;
24
(
1
):
570
.
5.
Houamel
D
,
Ducrot
N
,
Lefebvre
T
,
Daher
R
,
Moulouel
B
,
Sari
MA
.
Hepcidin as a major component of renal antibacterial defenses against uropathogenic Escherichia coli
.
J Am Soc Nephrol
.
2016
;
27
(
3
):
835
46
.
6.
Ganz
T
,
Nemeth
E
.
Iron balance and the role of hepcidin in chronic kidney disease
.
Semin Nephrol
.
2016
;
36
(
2
):
87
93
.
7.
Leaf
DE
,
Rajapurkar
M
,
Lele
SS
,
Mukhopadhyay
B
,
Boerger
EAS
,
Mc Causland
FR
.
Iron, hepcidin, and death in human AKI
.
J Am Soc Nephrol
.
2019
;
30
(
3
):
493
504
.
8.
Wang
G
.
Human antimicrobial peptides and proteins
.
Pharmaceuticals
.
2014
;
7
(
5
):
545
94
.
9.
Diepeveen
LE
,
Laarakkers
CM
,
Peters
HPE
,
van Herwaarden
AE
,
Groenewoud
H
,
IntHout
J
.
Unraveling hepcidin plasma protein binding: evidence from peritoneal equilibration testing
.
Pharmaceuticals
.
2019
;
12
(
3
):
123
.
10.
Kuragano
T
,
Furuta
M
,
Shimonaka
Y
,
Kida
A
,
Yahiro
M
,
Otaki
Y
.
The removal of serum hepcidin by different dialysis membranes
.
Int J Artif Organs
.
2013
;
36
(
9
):
633
9
.
11.
Matejovic
M
,
Chvojka
J
,
Radej
J
,
Ledvinova
L
,
Karvunidis
T
,
Krouzecky
A
.
Sepsis and acute kidney injury are bidirectional
.
Contrib Nephrol
.
2011
;
174
:
78
88
.
12.
Mehta
RL
,
Bouchard
J
,
Soroko
SB
,
Ikizler
TA
,
Paganini
EP
,
Chertow
GM
.
Sepsis as a cause and consequence of acute kidney injury: program to improve care in acute renal disease
.
Intensive Care Med
.
2011
;
37
(
2
):
241
8
.
13.
Litton
E
,
Lim
J
.
Iron metabolism: an emerging therapeutic target in critical illness
.
Crit Care
.
2019
;
23
(
1
):
81
.
14.
Nemeth
E
,
Tuttle
MS
,
Powelson
J
,
Vaughn
MB
,
Donovan
A
,
Ward
DM
.
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization
.
Science
.
2004
;
306
(
5704
):
2090
3
.
15.
Billesbølle
CB
,
Azumaya
CM
,
Kretsch
RC
,
Powers
AS
,
Gonen
S
,
Schneider
S
.
Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms
.
Nature
.
2020
;
586
(
7831
):
807
11
.
16.
Roetto
A
,
Papanikolaou
G
,
Politou
M
,
Alberti
F
,
Girelli
D
,
Christakis
J
.
Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
.
Nat Genet
.
2003
;
33
(
1
):
21
2
.
17.
Griffin
BR
,
Thomson
A
,
Yoder
M
,
Francis
I
,
Ambruso
S
,
Bregman
A
.
Continuous renal replacement therapy dosing in critically ill patients: a quality improvement initiative
.
Am J Kidney Dis
.
2019
;
74
(
6
):
727
35
.
18.
Honoré
PM
,
Jacobs
R
,
Joannes-Boyau
O
,
De Waele
E
,
Van Gorp
V
,
Boer
W
.
Con: dialy- and continuous renal replacement (CRRT) trauma during renal replacement therapy: still under-recognized but on the way to better diagnostic understanding and prevention
.
Nephrol Dial Transplant
.
2013
;
28
(
11
):
2723
7
; discussion 2727–8.
19.
Sharma
S
,
Brugnara
C
,
Betensky
RA
,
Waikar
SS
.
Reductions in red blood cell 2,3-diphosphoglycerate concentration during continuous renal replacment therapy
.
Clin J Am Soc Nephrol
.
2015
;
10
(
1
):
74
9
.
20.
Umber
A
,
Wolley
MJ
,
Golper
TA
,
Shaver
MJ
,
Marshall
MR
.
Amino acid losses during sustained low efficiency dialysis in critically ill patients with acute kidney injury
.
Clin Nephrol
.
2014
;
81
(
2
):
93
9
.
21.
Oh
WC
,
Mafrici
B
,
Rigby
M
,
Harvey
D
,
Sharman
A
,
Allen
JC
.
Micronutrient and amino acid losses during renal replacement therapy for acute kidney injury
.
Kidney Int Rep
.
2019
;
4
(
8
):
1094
108
.
22.
Ostermann
M
,
Summers
J
,
Lei
K
,
Card
D
,
Harrington
DJ
,
Sherwood
R
.
Micronutrients in critically ill patients with severe acute kidney injury: a prospective study
.
Sci Rep
.
2020
;
10
(
1
):
1505
.
23.
Seyler
L
,
Cotton
F
,
Taccone
FS
,
De Backer
D
,
Macours
P
,
Vincent
JL
.
Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy
.
Crit Care
.
2011
15
3
R137
.
24.
Thompson
AJ
.
Drug dosing during continuous renal replacement therapies
.
J Pediatr Pharmacol Ther
.
2008
;
13
(
2
):
99
113
.
25.
Yin
F
,
Zhang
F
,
Liu
S
,
Ning
B
.
The therapeutic effect of high-volume hemofiltration on sepsis: a systematic review and meta-analysis
.
Ann Transl Med
.
2020
;
8
(
7
):
488
.
26.
Payen
D
,
Mateo
J
,
Cavaillon
JM
,
Fraisse
F
,
Floriot
C
,
Vicaut
E
.
Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial
.
Crit Care Med
.
2009
;
37
(
3
):
803
10
.
27.
Mayumi
K
,
Yamashita
T
,
Hamasaki
Y
,
Noiri
E
,
Nangaku
M
,
Yahagi
N
.
Impact of continuous renal replacement therapy intensity on septic acute kidney injury
.
Shock
.
2016
;
45
(
2
):
133
8
.
28.
Casu
C
,
Nemeth
E
,
Rivella
S
.
Hepcidin agonists as therapeutic tools
.
Blood
.
2018
;
131
(
16
):
1790
4
.
29.
Pemmaraju
N
,
Kuykendall
A
,
Kremyanskaya
M
,
Ginzburg
Y
,
Ritchie
E
,
Gotlib
J
.
MPN-469 rusfertide (PTG-300) treatment interruption reverses hematological gains and upon reinitiation, restoration of clinical benefit observed in patients with polycythemia vera
.
Clin Lymphoma Myeloma Leuk
.
2022
22
Suppl 2
S338
9
.
You do not currently have access to this content.